SCHEDULE: Soleus Capital Reports 3.7% Stake in Rigel Pharma

Soleus Capital Master Fund and related entities report a 3.7% beneficial ownership stake in Rigel Pharmaceuticals, Inc. as of June 30, 2025.

Summary

• Soleus Capital Master Fund, L.P., along with Soleus Capital, LLC, Soleus Capital Group, LLC, Soleus Capital Management, L.P., Soleus GP, LLC, and Guy Levy, collectively reported beneficial ownership of 658,145 shares of Rigel Pharmaceuticals, Inc. common stock.
• This ownership represents 3.7% of Rigel Pharmaceuticals' outstanding common stock.
• The percentage is calculated based on 17,872,432 shares outstanding as of May 1, 2025, as reported in Rigel's Quarterly Report on Form 10-Q for the period ended March 31, 2025.
• The reporting persons have shared voting and shared dispositive power over all 658,145 shares.
• The shares were not acquired or held for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of passive beneficial ownership, indicating a neutral sentiment as it does not convey positive or negative operational news or strategic intent beyond investment.

Future Outlook

This filing is a Schedule 13G, which reports passive beneficial ownership and does not contain forward-looking statements or guidance from the issuer.

Industry Context

This filing indicates a passive investment by Soleus Capital in Rigel Pharmaceuticals, a company operating in the biotechnology and pharmaceutical sector. Such filings are routine disclosures of significant ownership stakes by institutional investors, reflecting their portfolio allocations rather than direct operational or strategic shifts within the industry.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant, albeit passive, institutional ownership stake in the company.

Key Dates

Keywords

Rigel Pharmaceuticals, Soleus Capital, Beneficial Ownership, SEC Filing, Common Stock, Investment, Pharmaceuticals, Biotechnology